Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

84.69 +0.16 (+0.19%)
Streaming Delayed Price Updated: 3:40 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
From AstraZeneca
Via Business Wire
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump
Via Stocktwits
AstraZeneca Announces $4.5B Investment In Virginia
Via Stocktwits
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies. 
Via Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs
AstraZeneca will invest $4.5 billion in a Virginia facility, creating 3,600 jobs and producing advanced cancer and metabolic medicines using AI and automation. 
Via Benzinga
Topics Artificial Intelligence
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
From AstraZeneca
Via Business Wire
A Look Into AstraZeneca Inc's Price Over Earnings
 
Via Benzinga
Should You Forget Nvidia and Buy These 2 Millionaire-Maker Stocks Instead?
These two up-and-coming tech stocks just might make investors more money over the next decade than Nvidia will. 
Via The Motley Fool
Topics Artificial Intelligence
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension
AstraZeneca's Baxdrostat cut 24-hour systolic blood pressure in a Phase 3 trial, showing promise for treatment-resistant hypertension patients. 
Via Benzinga
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
From AstraZeneca
Via Business Wire
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices
Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions. 
Via Benzinga
Topics Government
AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases
Algen Biotechnologies partners with AstraZeneca in a $555 million deal to advance AI-driven CRISPR drug discovery and novel immunology therapies. 
Via Benzinga
Topics Artificial Intelligence
AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy
AstraZeneca and Daiichi Sankyo's Datroway improved survival outcomes over chemotherapy in advanced triple-negative breast cancer patients. 
Via Benzinga
Are Pure Play Quantum Computing Stocks a Buy in October?
Quantum stocks have mooned in 2025, raising questions about whether their sky-high valuations reflect real breakthroughs or just speculation. 
Via The Motley Fool
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
From AstraZeneca
Via Business Wire
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca... 
Via MarketMinute
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
2 Under-The-Radar Health-Tech Stocks With Surging Momentum Scores
Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings. 
Via Benzinga
Investing in These 3 Quantum Computing Stocks Could Be a Once-in-a-Lifetime Opportunity
All of these rising quantum computing stars could be massive winners over the long run. 
Via The Motley Fool
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?
The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now. 
Via The Motley Fool
Topics Government World Trade
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth
AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York... 
Via MarketMinute
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.